Targeting genes involved in the responses to replication stress and DNA DSBs repair, such as MRE11, RAD51, RAD52, and POLQ, alone or in combination with DNA damaging agents and checkpoint inhibitors, might be a strategy to expand the spectrum of systemic therapeutic options, thus tailoring CRC treatments and improving the disease prognosis. Here, RAD52 is linked to colorectal carcinoma.